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A B S T R A C T
In this article, the authors have gathered data from epidemiological, observational, case-control and cohort studies to
evaluate the differences between men and women in terms of ischemic events, mainly stroke. The authors are highlight-
ing the differences that exist between men and women and play a role in terms of social diversities, and the
pathophysiological differences that may be responsible at least in part for ischemic events. Studies show that male stroke
patients are more likely to have a history of ischemic heart disease, smoking and alcohol consumption, whereas female
stroke patients suffer from ischemic events at an older age, are more likely to have hypertension and atrial fibrillation.
Women are more likely to arrive to an emergency room in a comatose state, with paralysis, aphasia, swallowing problems
and urinary incontinence, which all indicates a more severe stroke. Also, women suffer from a higher level of disability
than men, even though their survival rates are the same. Even though clear guidelines for the treatment of stroke exist,
there are still differences in both diagnostic procedures and discharge destination between male and female patients.
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Introduction
What are the differences between men and women? It
is well known that the XX and XY combinations deter-
mine not just sexual features but also other characteris-
tics which are not so easily detected. What is the extent
of diversities between men and women that play an im-
portant role and may influence, for instance – the preva-
lence, severity and outcome of stroke?
In this article, authors have gathered data from epide-
miological, observational, case-control and cohort studies
to evaluate the differences between men and women in
terms of ischemic events, mainly stroke. The objective of
this article is to discuss which are the differences that ex-
ist between genders and play a role in terms of social di-
versities, and the pathophysiological differences that
may be responsible at least in part for ischemic events. A
PubMed (from January 1966 through January 2008)
search of the literature in the English language was con-
ducted using the terms »stroke«, »sex differences«, »risk
factors«, »treatment« and »diagnostics«. Articles were
selected on the basis of relevance.
Differences in Risk Factors
Stroke is the second cause of mortality in Croatia; in
2006 cerebrovascular diseases were the cause of death in
4706 of women (18.7%) and in 3369 of men (13.3%)1. It is
a well known fact that genetic predisposition has great
influence on risk for stroke and several genes for certain
risks factors were identified. However lately a study has
established that heritability of ischemic stroke is greater
in women than in men: stroke in female family members
was more frequent if other female family members previ-
ously suffered from it, while male family members were
less likely to suffer from stroke. This difference was sta-
tistically significant even if traditional risk factors that
could explain these gender differences were taken into
consideration2.
In some studies, women presented with a profile of
higher baseline risk factors3,4,5. A study evaluating the
prevalence of risk factors in patients with myocardial in-
farction and their association with recurrent ischemic
events (including myocardial infarction, stroke and coro-
nary death) showed that women have more risk factors,
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and the risk of recurrent ischemic events in women in-
creased with hypertension, diabetes and hypercholester-
olemia, but for men, no increase in risk was detected
with any risk factor5.
Another study in patients undergoing coronary artery
bypass graft surgery showed that risk factors signifi-
cantly differ among sexes: women have hypertension and
intracranial artery stenosis more frequently than men,
while men are more likely to have hyperlipidemia, pe-
ripheral vascular disease, abdominal aortic aneurysm,
severe carotid stenosis and severe aortic atherosclerosis6.
(A study evaluating risk factors in middle aged (45–65
years) stroke patients showed that women had diabetes,
hypertension and hypercholesterolemia significantly more
often than men, while men had a history of ischemic
heart disease, smoking and alcohol consumption more of-
ten than women7. Male stroke patients are more likely to
have a history of ischemic heart disease, whereas female
stroke patients are more likely to have hypertension and
atrial fibrillation (AF); some studies found diabetes more
commonly in women, others in men4,8–12. Men are more
likely to smoke cigarettes, or to have been smokers previ-
ously in their lives than women11.
A study designed to identify risk factors for cryp-
togenic stroke revealed that low levels of high density li-
poprotein (HDL) cholesterol and high factor VII activity
were more frequently present in women while low level
of plasma folate, hypertension and current smoking were
risk factors for crytpogenic stroke in men13.
One study showed that women are more prone to
cardioembolic strokes and men to atherothrombotic and
lacunar strokes14. A study conducted in the Croatian
population has shown that stroke is more frequent in
men at 55–74 years of age whereas in women the highest
frequency of stroke was found between 65 and 84 years
of age15. The study also showed that small-vessel diseases
are the leading cause of stroke in both sexes; in women
cardioembolism takes second place and large-vessel dis-
ease third, whereas in men large-vessel disease is in the
second place and cardioembolism in third15.
An USA study found no sex difference in stroke sub-
type, infarction size or location in patients with ischemic
stroke16.
In some studies traditional risk factors (hypercholes-
terolemia, smoking, obesity) for stroke were analyzed
only in women. During an 11 year follow-up of 28000
women, over 45 years of age, scientists have established
that total cholesterol, LDL cholesterol, and total choles-
terol to HDL cholesterol ratio are significantly associated
with increased risk of ischemic stroke, increasing it up to
two times17.
Summary of studies that evaluated the prevalence of
risk factors for cerebrovascular and cardiovascular dis-
eases among women and men are shown in Table 1.
Smoking
It is a well known fact that smoking is a serious risk
factor for stroke. During 9 years of follow-up researchers
have found that smokers who smoked less than 15 ciga-
rettes a day had a 1.93 times greater risk of stroke includ-
ing a 2.15 times higher risk of intracerebral haematoma
and a 1.7 times higher risk of subarachnoidal haemor-
rhage (SAH). In women who smoked more than 15 ciga-
rettes a day, compared to women who never smoked, the
risk was 3.39; 2.67 and 4.02 respectively18.
Body mass index
Studies have shown that arterial wall stiffness index
differs according to body mass index (BMI). Compared to
women, men had higher arterial wall stiffness which can
probably be attributed to the protective effect of female
sex hormones since most of the examinees were of fertile
age19. One study established a connection between BMI
and ischemic but not hemorrhagic stroke in women: BMI
higher than 30 kg/m2 carries 1.5 times higher risk for any
type of stroke, namely 1.7 times for ischemic and 0.8 time
for hemorrhagic, in comparisons to women whose BMI
was lower than 25 kg/m2. However a satisfactory man-
agement of a patient’s hypertension, diabetes and high
cholesterol significantly lowers that risk20.
Atrial fibrillation
Out of patients with atrial fibrillation, women have
higher annual rates of ischemic stroke than men (3.5%
women, 1.8% men); however, there was no significant dif-
ference in sex in 30-day mortality or annual rates of hem-
orrhage (1% of both minor and major hemorrhage within
one-years follow-up)21. The authors of this study have
concluded that the female sex is an independent risk fac-
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TABLE 1
PREVALENCE OF RISK FACTORS FOR CEREBROVASCULAR AND
CARDIOVASCULAR DISEASES AMONG WOMEN AND MEN
Risk factor Women Men Reference
Inheritance + 2
Atrial fibrillation + 8,11,21
Low HDL cholesterol + 13
Factor VII high activity + 13,25
Hypercoagulable state + 23
Migraine with aura + 40,41
Intracranial stenosis + 2,6
Peripheral artery disease + 2,6
Ischemic heart disease + 7,8,11
Smoking + 6,7,11,13
Alcohol consumption + 7
Carotid stenosis + 2,6
Abdominal aortic aneurysm + 2,6
Low folate + 13
D-dimers + 25
Diabetes mellitus + +* 5,7,8*
Hypertension + +* 5,6,7,8,11,13*
Hyperlipidemia +* + 2,6,5*
tor for thromboembolism which goes in favour of intro-
ducing anticoagulant therapy in women with AF21.
Another study has shown gender-related differences
in patients with AF. Women were older, had a lower qual-
ity of life, more often had heart failure with preserved
left ventricular systolic function, less frequently under-
went electrical cardioversion and achieved rhythm con-
trol, and had a higher level of risk for stroke. However,
prescription of oral anticoagulants was identical in both
genders (65%) and so was the mortality22. Yet another
study, which examined gender-related differences in war-
farin treatment of patients with AF, showed that women
were older than men, had more risk factors, experienced
more overall (major and minor) hemorrhages and had a
higher rate of thromboembolism3.
Coagulation
It has been observed that women are more prone to a
hypercoagulable state than men early after injury23. Pos-
sibly an underlying mechanism such as coagulation sta-
tus is an important factor in patients with stroke as well.
Differences in coagulation parametes have been obser-
ved between men and women: women with diabetes
mellitus have abnormalities in euglobulin clot lysis time
and increased plasminogen activator inhibitor-124. Ele-
vated levels of factor VIIa are associated with an in-
creased risk of recurent cardiac events in postinfarction
women but not in men while D-dimers are more predic-
tive in men for cardiac events25. These observations indi-
cate possible gender-related differences in the patho-
physiologic mechanisms of recurrent cardiac events.
Environmental factors
There is an interesting study that analyzed the effect
of air pollution on stroke incidence in women in meno-
pause. During a 4 year follow-up scientists monitored air
pollution in 36 urban areas in the USA and they con-
cluded that an increase in air pollution of 10 micrograms
per cubic meter increased the risk of stroke 1.24 times
and cerebrovascular and cardiovascular mortality rate
1.76 times26.
Female hormones
In the past decade, HRT at menopause has been a
subject of great debate, and many studies have dealt with
the correlation between hormones, especially estrogen,
and stroke. One study showed that the risk of stroke
caused by non-cardioembolic etiology was increased in
women with hypertension, diabetes, hyperlipidemia, a
lifespan of ovarian activity that exceeded 34 years and
the onset of menarche at 13 years of age or younger; and
yet women with obesity were found to have a lower risk
of stroke27.
WHI (Women’s Health Initiative) study examined the
effect of combined HRT (estrogens plus progestins) and
just estrogen therapy in women at menopause28. The seg-
ment of the study in which women received combined
HRT was prematurely terminated (after 5.2 years) due to
the fact that combined HRT showed a positive correla-
tion with an increased risk for stroke, coronary heart dis-
ease, venous thromboembolism and breast cancer compa-
red to women who were receiving placebo. The remain-
ing segment of the study (women who were receiving
only estrogen) did not show a positive correlation with an
increased risk of cardiovascular diseases or breast cancer.
The study also showed that HRT decreases the risk of
bone fractures and rectal carcinoma. The study con-
cluded that there is a need for individual approach in
HRT, which should be given at early menopause and dis-
continued after a maximum of 5 years, and that special
attention and more intense follow-up should be given to
women with a positive family history of breast cancer, di-
agnosed coronary disease or a predisposition to deep ve-
nous thrombosis28. However, the authors of this study
were criticized because the women in this study were rel-
atively old, and the risk was calculated as relative rather
than absolute, hence critics suggest that different results
would have been obtained had younger, healthier women
with a generally lower risk of stroke been included. Fur-
thermore, this study did not take into consideration va-
somotor symptoms, which cause a considerate number of
postmenopausal women severe everyday difficulties. These
menopausal symptoms can be aleviated by use of HRT,
which can outweigh the relative long-term risks found in
the WHI study29. This was tested and confirmed in a
group of postmenopausal women: even though they have
been well informed about the results of the WHI study
and it’s implications on their health, a number of wo-
men, especially those with risk factors for coronary dis-
ease, refused to terminate their HRT30. Another study
showed that 87% of women discontinued their HRT after
the publication of results from the WHI study, but due to
various vasomotor symptoms (which occured in 85% of
examinees) 26% of women restarted HRT31.
Caution is necessary considering the fact that yet an-
other double-blind randomised study found that estro-
gen is without benefitial effect in postmenopausal wo-
men who have suffered stroke, in fact women who were
randomly assigned to receive estrogen therapy had a
higher risk of fatal stroke and their nonfatal strokes
were associated with slightly worse neurologic and func-
tional deficits32.
When all of these studies dealing with the correlation
between HRT and stroke have been combined, it was
concluded that HRT increases the relative risk of is-
chemic stroke and coronary incident as well as venous
thromboembolism, but decreases the risk of fatal stro-
ke28,33. It seems like female hormons play a significant
protective role in women’s life in their fertile age, since
studies have shown that women aged 45 to 54 years have
significantly higher odds of experiencing a stroke com-
pared to men of the same age34.
There was no increase in risk of either stroke or myo-
cardial infarcton found in younger women which use oral
contraceptives, regardless whether they used pills or con-
traceptive patches35. However, another study showed
that women who used transdermal patches had a twice
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increased risk of venous thrombombolism when com-
pared to women who used contraceptive pills36.
Migraine
Studies have shown that there is a correlation be-
tween headaches, namely migraine with aura, and stroke
which is of great importance if we take into consideration
the fact that the prevalence of migraine is far greater in
women than in men37,38. One population based study exa-
mined the correlation between chronic unspecified head-
ache and stroke and found that the risk of stroke in men
who have had headaches during the past year is 4 times
higher than in those without headaches, whereas that
risk was only 2 times higher in men with headaches dur-
ing the past 5 years. Among women, there was also a di-
rect but statistically nonsignificant association between
headache and the risk of stroke, thus the authors have
concluded that chronic headache is an independent pre-
dictor of stroke among men and that it may be a marker
of the underlying disease process leading to acute stroke
seeing how the connection was strongest during a 1-year
follow-up39.
In a study including 3610 women with active mi-
graine, 39.7% had migraine with aura; compared with
women with no migraine history, these women had in-
creased hazard ratios for stroke: 1.91 for ischemic stroke,
2.08 for myocardial infarction, 1.74 for coronary reva-
scularization, 1.71 for angina, and 2.33 for death due to
ischemic cardiovascular disease40.
A similar study failed to find a correlation between
migraine without aura or ordinary headache and is-
chemic or hemorrhagic stroke, but found a connection
between migraine with aura and stroke; these women
had a 1.71 times increased risk of ischemic stroke, even
in women 55 years of age and younger. However, this is
an increase in relative risk; in terms of absolute risk this
means only 3.8 additional cases per year per 10000
women41.
Women aged 15 to 49 years with probable migraine
with aura have a 1.5 increased risk for stroke, and
women who use oral contraceptives or smoke have even a
7 fold increased risk for stroke compared with women
with probable migraine with aura who are non-smokers
or do not use oral contraceptives42. Sub-analysis from the
Women’s Health Study revealed that women who have
active migraine without aura do not have an increased
risk for any cerebrovascular events, but women with ac-
tive migraine with aura have a 2 fold increased risk for
major cardiovascular disease and stroke compared with
women with no migraine43. Since migraine has a complex
pathophysiology, especially migraine with aura, which in-
cludes vascular mechanisms, the connection between mi-
graine and stroke may have similar background44,45.
Awareness of Stroke
Whether there are significant differences between
males and females in terms of stroke is difficult to say.
However, studies have shown some really interesting and
sometimes unexpected results.
First of all, studies have proved that general knowl-
edge of stroke risk factors is rather poor. Epidemiological
population studies in the USA which examined the knowl-
edge of stroke risk factors and early signs of stroke have
shown that the understanding of stroke has improved in
the last decade: only 11% of women reported feeling un-
informed about stroke compared to 23% of women in
1997. This change is more prominent in ethnical minori-
ties (Hispanics and African American), which shows that
the education about stroke should be directed primarily
toward ethnical minorities46.
Another study conducted in the USA in 2003 showed
that only 26% of women, aged 65 and older, consider
themselves well informed about stroke, even though that
age group has the highest risk of stroke; very few women
were able to properly identify signs of stroke: 39% men-
tioned one sided palsy and 29% stated speech disorder
and inability to understand speech47. Twenty percent of
women in that study reported being constantly worried
that stroke could happen to them. A survey in the Cro-
atian population showed that over 50% of examinees are
aware that speech disorder, paresthesias in the limbs as
well as weakness of the extremities and body parts are
signs of acute stroke. Accordingly more than 50% of
them stated stress, hypertension, smoking, high blood
lipids and adiposity as stroke risk factors48.
Diagnostics, Clinical Differences, Therapy,
Outcome
Although there are clear guidelines for treatment of
stroke49,50, certain studies revealed that there are still
differences in both diagnostic procedures and discharge
destinations between male and female patients. A Cana-
dian study found a statistically significant differences in
hospital discharges of patients after having suffered a
stroke8. Male patients were more likely than women to
be discharged home, while female patients were more
likely to be discharged to chronic care facilities. This
study does not specify the physical state of the patients
at the time of hospital discharge, still it leads us to be-
lieve that women were left with a greater neurological
deficit and required constant care in an institution8. The
observation in some studies that women seem to receive
health care later than men (studies conducted in devel-
oped countries) seemed astonishing, however, this might
be due to social differences which are still not eradicated
in some countries, perhaps in more rural regions, but
detalied epidemiological data in these studies are not
available. The observation that women are not treated
equally to men should be taken coutiously; certain epide-
miological studies have posed this question, however, re-
cent studies have proven the opposite, may we say fortu-
nately for women. The fact that women are more often
instutionalized after stroke, could also be partly due to
social circumstances, since the data reagarding the disa-
bilty after stroke are inconsistent.
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A study performed in 7 European countries investi-
gated demographic factors, risk factors, clinical presenta-
tion and 3-month outcome in patients with a first-in-a-
-lifetime stroke9. The study showed that, clinically, women
in the acute stage were more likely to present with coma,
paralysis, aphasia, inability to swallow and urinary in-
continence, which would suggest a more severe stroke
type. Amazingly brain imaging, Color Doppler of extra
and intracranial arteries, echocardiogram and angiogra-
phy were significantly less frequently performed in wo-
men than in men. After a 3-month follow-up women
showed higher levels of disability and handicap than
men, although no significant gender effect was observed
on survival.
A study from Spain showed that women suffered
from aphasic disorders, visual field disturbances and
dysphagia more often than men, and women who sur-
vived stroke were more disabled at discharge14. Study
from Israel showed no gender differences in clinical pre-
sentation or imaging studies, but the in-hospital mor-
tality rate among women was higher as compared with
men7.
In a Canadian study, stroke symptoms at presentation
were similar in women and men, except that women
were more likely to present with headaches and were less
likely to have brain stem or cerebellar symptoms; in this
study, there were no sex differences in the use of neuro-
imaging, thrombolysis, antithrombotic therapy or con-
sultations51. However, in studies analyzing vascular sur-
gical mortality, unadjusted, all-cause 30-day mortality
was higher in women than in men following coronary ar-
tery bypass graft procedure and primary stenting for
acute myocardial infarction; on multivariate analysis fe-
male gender was not an independent risk factor52,53. In-
dependent determinant of overall adverse outcomes and
higher mortality rate in women after interventional treat-
ment for acute myocardial infarction was observed, which
was explained with a greater prevalence of traditional
risk factors such as diabetes, hypertension and hyper-
lipidemia in women12.
A study from Germany found no differences in diag-
nostic procedures performed at baseline and in follow-up
management between men and women, there were also
no differences in regard to the need for nursing su-
pport54. Analysis of stroke recovery and stroke-specific
quality of life in USA showed that female stroke survi-
vors had lower functional recovery and poorer quality of
life three months post-discharge compared to men; these
differences could not be explained by older age at stroke
onset or other demographic or clinical characteristics55.
In a Canadian study, mortality was similar in men and
women but women were more likely to be discharged to
long-term care facilities and had greater disability after 6
months51.
An USA study found that a greater proportion of
women presented with weakness than men but no differ-
ence was observed in presentation of other stroke symp-
toms such as numbness, visual deficits or language16.
Differences also exist in stroke treatment and use of
medication. When evaluating 90-day postdischarge use
of aspirin and ticlopidine in stroke survivors aged 85
years or more, men were more likely than women to re-
ceive both drugs, however use of warfarin was similar for
both sexes8. A German study revealed that women were
significantly more likely to receive hypoglicemic drugs in
the acute management period54.
Early arrival to an emergency facilty is one of the ma-
jor requirements for treatment with thrombolysis, yet a
study from Germany found that women have a 10%
lower chance of being admitted within the first 3 hours
than men and this chance is further decreased in older
women; however, there was no sex differences in the
chance of being treated with thrombolysis if the patients
were admitted within this time window56. In the time
window between 0 and 3 hours, men had elevated mor-
tality as compared with women but were approximately
three times as likely to have good functional outcomes57.
However, women were significantly more likely to bene-
fit from rtPA compared with men in a therapy window
between 0 and 6 hours58. Similarly, the PROACT-2 study
of intra-arterial stroke thrombolysis with prourokinase
has shown that women have 20% absolute benefit com-
pared with men (10% absolute benefit)59. In contrast to
these studies, a study from Switzerland has shown no
differences between sex and recanalization or outcome
after 3 months in patients treated with intra-arterials
thrombolysis60. Observations from these studies need to
be proved in future studies; sex may be an important fac-
tor for selection for thrombolysis especially in patients
presenting at later time from symptom onset.
Women have worse survival and mortality rates com-
pared with men in some studies7,12,53,54 while in other
studies men have worse mortality rates8,23 and in some
studies rates show no significant difference10,52,61. Consi-
stent data are shown for disability: women are more disa-
bled after suffering a stroke or other ischemic event10,14,52,56.
Case fatality (deaths caused by cerebrovascular dis-
eases among cases of acute stroke) for both ischemic
stroke and all types of stroke combined was higher in men
than in women, as was case mortality (deaths attributable
to any cause among cases of acute stroke); however there
was no difference in mortality caused by SAH61.
Carotid Endarterectomy in Women
and Differences in Plaque Composition
The existing literature provides conflicting evidence
concerning the risks of carotid endarterectomy (CEA) in
women as compared with men. The initial NASCET and
ECST62 studies have found that asymptomatic women
benefit, in terms of postoperative results, from CEA less
than asymptomatic men or symptomatic patients in gen-
eral, however recent studies have shown that these dif-
ferences are not clear enough to suggest that women
shouldn’t be surgically treated.
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A recent study on 3422 CEA patients has shown that
women were at higher risk for a postoperative TIA or
stroke and for postoperative stroke or mortality63. This
difference was visible only in asymptomatic women while
there was no gender association for postoperative stroke
or mortality for patients who were symptomatic. The au-
thors of this study have concluded that although the
combined TIA or stroke and stroke or mortality rates are
higher in asymptomatic women as compared with men in
the postoperative period, CEA is still appropriate in both
women who are asymptomatic and women who are sym-
ptomatic but only if the postoperative TIA, stroke, and
mortality rates are appreciably lower than in the natural
history of medical management of these patients. Sub-
group analysis in a study evaluating CEA in asymptom-
atic patients showed that women had a lower risk of
ipsilateral ischemic stroke on medical treatment and a
higher operative risk than did men, whereas CEA was
beneficial in symptomatic severe carotid stenosis64. An-
other study found no difference in 30-day surgical mor-
tality after CEA52.
A study done on a sample of 6038 CEA patients (out of
which 35% were women), showed that there was no sig-
nificant gender difference in the perioperative risk of
stroke or death, however, after a 2-year follow-up, wo-
men were more likely to have a stroke yet less likely to
die65. Another study, which evaluated the perioperative
risks of over 1200 CEA patients (out of which 39% were
women) during a 21-year period, found that survival
rates at 1.5 and 8 years were higher for asymptomatic
and symptomatic women compared with men, thus con-
cluding that CEA does not carry a higher level of risk for
women10. Yet another study, examined the data collected
over a period of 8 years, evaluating the outcome of 1298
CEA patients, and found that women were more likely to
be asymptomatic than men but that there was no gen-
der-difference in the frequency of postoperative cardiac
(2.5% women, 1.5% men) or neurological events (1.6%
women, 2.1% men); the postoperative stroke rate was
1.5% with no significant difference between men and
women, and late recurrent stenosis developed in 1.5% of
women and 0.8% of men, once again showing no signifi-
cant gender-difference11.
One other study, evaluating the arteriotomy closure
after CEA, found that primary closure was signifi-
cantly gender related (Dacron patch, 35 men and 30
women; venous patch, 108 men and 63 women; pri-
mary closure, 72 men and 11 women), as was the occur-
rence of microemboli during wound closure (women
2.5±0.6; men 1.0±0.2)66. Dacron patches were associ-
ated with significantly more microemboli than venous
patches and venous patch closure had the lowest reste-
nosis rate, thus the authors suggest that venous patch
closure may be preferred for CEA66.
One study found that women who have previously had
stroke or a TIA have a somewhat increased perioperative
risk (although not significantly), the stroke-free survival
rate was not significantly different between genders and
neither was the restenosis rate, but the use of hormone re-
placement therapy (HRT) showed a trend towards in-
creasing 30-day and 5-year stroke rates67. These results go
in favour of discontinuing HRT in case of stroke.
Based on all of this recent evidence, we could say that
there are no gender-differences in perioperative risks of
CEA.
Some studies have attempted to find an explanation
for clinical differences in postoperative outcome between
men and women in atherosclerotic carotid plaque pheno-
type. In women, atheromatous plaques (>40% fat) were
less frequent (22% in women, 40% in men), contained
less macrophages (11% women, 18% men) but more
smooth muscle cells (38% women, 24% men)68. Also,
compared with men, women had a lower plaque concen-
tration of IL-8 and lower metalloproteinase-8 activity.
The observed differences were most pronounced in asym-
ptomatic women, who showed the most stabile plaques.
Generally, a large proportion of plaques found in asymp-
tomatic women had high smooth muscle cell content and
high collagen content68.
Microemboli can be found in various clinical cases,
and more than 70% of symptomatic patients with carotid
stenosis have positive embolic signals which can be de-
tected by means of transcranial Doppler (TCD)69. Clini-
cal studies have shown that, intraoperatively, micro-
emboli are more common in patients with fibrous plaques
but that the risk for cerebrovascular complications is
greater in patients with atheromatous (lipid) plaques70.
One study found that atheromatous plaques were more
prevalent in patients with stroke and TIA compared with
asymptomatic patients or patients with amaurosis fugax,
also plaques of patients with TIA and stroke showed sig-
nificantly higher levels of MMP-8, MMP-9 and inter-
leukin-871.
Other studies have shown that the morphology of
atherosclerotic plaques changes with aging; metallopro-
teinase-2 (MMP-2) activity was negatively and metallo-
proteinase 9 (MMP-9) activity positively related with age,
furthermore plaques become more atheromatous and
contain less smooth muscle cells with increasing age, and
local inflammation and MMP-9 levels are increased with
age in patients suffering from haemodynamically signifi-
cant atherosclerotic lesions72.
MMP-2 and MMP-9 levels were significantly higher in
symptomatic patients with carotid artery stenosis who
underwent CEA (the study included 67.5% symptomatic
and 32.5% asymptomatic patients) as well as in patients
with unstable plaques compared with those with stable
plaques73. In addition, a strong association between ele-
vated MMP-9 concentration (greater than 607 ng/mL)
and the presence of macrophages in plaque was found.
Measuring the concentration of these metalloproteinasas
can help in identifying patients with an increased risk for
stroke, especially in women, considering the fact that one
study had found that the risk of postoperative micro-
embolic signals was greater in women, patients not re-
ceiving antiplatelet therapy, and patients undergoing
left-sided CEA74.
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Conclusions
Studies show that women are older when they suffer
from stroke, myocardial infarction or other ischemic
event. The distribution of risk factors such as hyperten-
sion, diabetes and hyperlipidemia between genders is in-
consistent; men have a history of ischemic heart disease,
vascular peripheral disease, carotid artery stenosis, aor-
tic atherosclerosis, smoking and alcohol consumption
more often than women while women more frequently
suffer from cardioembolic strokes and men from athero-
thrombotic. Inconsistent are the data regarding the per-
formance of diagnostic procedures: some studies have
found no difference between sexes, and others found less
procedures being performed in women. Recent studies
found no gender difference whether CEA is appropriate
in asymptomatic women therefore CEA in women is rec-
ommended equaly as in men. Differences observed be-
tween men and women regarding thrombolysis up to
date still need further evaluation. Although data from
observational or case control studies are appreciated as
well, only large cohort studies can give us answers which
can be implemented into treatment guidelines.
Finally we can conclude that gender differences do ex-
ist, and that they are not shaped soley by genetic factors
but also by environmental and social influences.
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MO@DANI UDAR KOD @ENA: KOLIKO SE @ENE I MU[KARCI RAZLIKUJU?
PRIKAZ LITERATURE – DIJAGNOSTIKA, RAZLIKE U KLINI^KOJ SLICI, TERAPIJA I ISHOD
S A @ E T A K
U ovom ~lanku autori su prikupili podatke iz epidemiolo{kih, opservacijskih, kontroliranih i kohortnih studija s
ciljem utvr|ivanja razlike izme|u `ena i mu{karaca u odnosu na u~estalost ishemijskih incidenata, uglavnom mo`da-
nog udara. Autori nagla{avaju razlike koje postoje izme|u `ena i mu{karaca u sociolo{kim i patofiziolo{kim zna~ajkama
a koje barem djelomi~no imaju ulogu u razvoju ishemijskih incidenata. Studije pokazuju da mu{karci ~e{}e imaju ishe-
mijsku bolest srca i ~e{}e su pu{a~i i konzumenti alkohola dok `ene obolijevaju od ishemijskih incidenata u starijoj dobi,
~e{}e imaju hipertenziju i fibrilaciju atrija. @ene se u akutnoj fazi mo`danog udara klini~ki ~e{}e prezentiraju u koma-
toznom stanju, s plegijom, afazijom, pote{ko}ama gutanja i urinarnom inkontinencijom {to sve upu}uje na te`i mo`dani
udar. @ene tako|er imaju te`u razinu invalidnosti i onesposobljenosti u odnosu na mu{karce, iako je stopa pre`ivlja-
vanja je ista. Premda postoje jasne smjernice za lije~enje mo`danog udara zapanjuju}e je da postoje razlike u dijagno-
sti~kim postupcima te mjestu upu}ivanja na daljnje lije~enje ili smje{taj nakon otpu{tanja iz bolnice izme|u `ena i
mu{karaca.
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